v3.26.1
Basis of Presentation - Additional Information (Details) - USD ($)
1 Months Ended 3 Months Ended
Sep. 11, 2024
Feb. 25, 2024
Oct. 31, 2025
Sep. 30, 2024
Feb. 29, 2024
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2025
Sep. 11, 2025
Jul. 31, 2025
Subsidiary, Sale of Stock [Line Items]                    
Accumulated Deficit           $ 311,209,000   $ 307,873,000    
Net cash used in operating activities           (5,049,000) $ (5,925,000)      
Cash and cash equivalents           35,459,000 $ 16,310,000 35,461,000    
Extension period (in days)                   90 days
Financed insurance premiums           $ 18,768,000   13,030,000    
Minimum | Hardware                    
Subsidiary, Sale of Stock [Line Items]                    
Revenue, usage period           8 months        
Maximum | Hardware                    
Subsidiary, Sale of Stock [Line Items]                    
Revenue, usage period           1 year 8 months        
WTI Loan Facility | Term Loan                    
Subsidiary, Sale of Stock [Line Items]                    
Term loan facility $ 15,000,000                  
Extension period (in days) 90 days                  
Principal outstanding           $ 6,259,000   7,012,000    
Financed insurance premiums           5,191,000   5,609,000    
WTI Loan Facility | Term Loan | First Tranche Commitment                    
Subsidiary, Sale of Stock [Line Items]                    
Term loan facility $ 10,000,000                  
ABL Line of Credit | Line of Credit                    
Subsidiary, Sale of Stock [Line Items]                    
Financed insurance premiums           $ 13,353,000   $ 6,932,000    
ABL Line of Credit | Line of Credit | Revolving Credit Facility                    
Subsidiary, Sale of Stock [Line Items]                    
Maximum borrowing capacity $ 15,000,000               $ 20,000,000  
Additional maximum borrowing capacity                 $ 5,000,000  
Customer 1 | Customer Concentration Risk | Revenue Benchmark                    
Subsidiary, Sale of Stock [Line Items]                    
Concentration risk percentage           26.00% 37.00%      
Customer 1 | Customer Concentration Risk | Accounts Receivable                    
Subsidiary, Sale of Stock [Line Items]                    
Concentration risk percentage           29.00%        
Customer 2 | Customer Concentration Risk | Revenue Benchmark                    
Subsidiary, Sale of Stock [Line Items]                    
Concentration risk percentage           11.00% 14.00%      
Customer 2 | Customer Concentration Risk | Accounts Receivable                    
Subsidiary, Sale of Stock [Line Items]                    
Concentration risk percentage           14.00%        
Customer 3 | Customer Concentration Risk | Revenue Benchmark                    
Subsidiary, Sale of Stock [Line Items]                    
Concentration risk percentage           11.00%        
Customer 3 | Customer Concentration Risk | Accounts Receivable                    
Subsidiary, Sale of Stock [Line Items]                    
Concentration risk percentage           12.00%        
September 2024 Offering                    
Subsidiary, Sale of Stock [Line Items]                    
Sale of stock, shares issued in transaction (in shares) 3,135,136   4,825,400              
Net proceeds from Initial Public Offering and Private Placement per unit (in dollars per share) $ 3.70   $ 7.15              
Consideration received $ 10,590,000   $ 32,109,000              
Proceeds received from issuance of common stock       $ 10,590,000            
Private Placement                    
Subsidiary, Sale of Stock [Line Items]                    
Sale of stock, shares issued in transaction (in shares) 750,000                  
Series B Convertible Preferred Stock | Private Placement                    
Subsidiary, Sale of Stock [Line Items]                    
Proceeds from issuance of preferred stock   $ 9,250,000     $ 9,250,000